Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Mar;67(3):531–536.

Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

H Martin, I McConnell, B Gorick, N C Hughes-Jones
PMCID: PMC1542632  PMID: 3038440

Abstract

A purified preparation of Epstein-Barr virus (EBV) has been shown to activate the classical complement pathway by direct interaction with the first component of complement, C1, without the intervention of antibody. No evidence was found for activation of the alternative pathway. Following classical pathway activation the specific affinity of EBV for B cells can be presumed to be lost since the virus will become opsonized for clearance by phagocytic cells bearing complement receptors, CR1 and CR3. This activation is further evidence that complement plays a role in defence mechanisms independently of antibody activity.

Full text

PDF
531

Images in this article

533Fig. 1
on p.533
534Fig. 2
on p.534
535Fig. 4
on p.535

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartholomew R. M., Esser A. F. Differences in activation of human and guinea pig complement by retroviruses. J Immunol. 1978 Nov;121(5):1748–1751. [PubMed] [Google Scholar]
  2. Bredt W., Wellek B., Brunner H., Loos M. Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun. 1977 Jan;15(1):7–12. doi: 10.1128/iai.15.1.7-12.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clas F., Loos M. Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun. 1981 Mar;31(3):1138–1144. doi: 10.1128/iai.31.3.1138-1144.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cooper N. R., Jensen F. C., Welsh R. M., Jr, Oldstone M. B. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med. 1976 Oct 1;144(4):970–984. doi: 10.1084/jem.144.4.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fraker P. J., Speck J. C., Jr Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978 Feb 28;80(4):849–857. doi: 10.1016/0006-291x(78)91322-0. [DOI] [PubMed] [Google Scholar]
  6. Gigli I., Porter R. R., Sim R. B. The unactivated form of the first component of human complement, C1. Biochem J. 1976 Sep 1;157(3):541–548. doi: 10.1042/bj1570541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heusser C., Boesman M., Nordin J. H., Isliker H. Effect of chemical and enzymatic radioiodination on in vitro human Clq activities. J Immunol. 1973 Mar;110(3):820–828. [PubMed] [Google Scholar]
  8. Hughes-Jones N. C., Gorick B. D. The binding and activation of the Clr-Cls subunit of the first component of human complement. Mol Immunol. 1982 Sep;19(9):1105–1112. doi: 10.1016/0161-5890(82)90321-2. [DOI] [PubMed] [Google Scholar]
  9. Jondal M., Klein G., Oldstone M. B., Bokish V., Yefenof E. Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol. 1976;5(4):401–410. doi: 10.1111/j.1365-3083.1976.tb00294.x. [DOI] [PubMed] [Google Scholar]
  10. Jønsson V., Wells A., Klein G. Receptors for the complement C3d component and the Epstein-Barr virus are quantitatively coexpressed on a series of B-cell lines and their derived somatic cell hybrids. Cell Immunol. 1982 Sep 15;72(2):263–276. doi: 10.1016/0008-8749(82)90474-9. [DOI] [PubMed] [Google Scholar]
  11. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  12. Loos M. Antibody-independent activation of C1, the first component of complement. Ann Immunol (Paris) 1982 Mar-Apr;133C(2):165–179. doi: 10.1016/0769-2625(82)90030-7. [DOI] [PubMed] [Google Scholar]
  13. Loos M., Wellek B., Thesen R., Opferkuch W. Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun. 1978 Oct;22(1):5–9. doi: 10.1128/iai.22.1.5-9.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McConnell I., Klein G., Lint T. F., Lachmann P. J. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol. 1978 Jul;8(7):453–458. doi: 10.1002/eji.1830080702. [DOI] [PubMed] [Google Scholar]
  15. McSharry J. J., Pickering R. J., Caliguiri L. A. Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology. 1981 Oct 30;114(2):507–515. doi: 10.1016/0042-6822(81)90230-0. [DOI] [PubMed] [Google Scholar]
  16. Morrissey J. H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  17. Nemerow G. R., Cooper N. R. Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol. 1981 Jul;127(1):272–278. [PubMed] [Google Scholar]
  18. Nemerow G. R., Jensen F. C., Cooper N. R. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest. 1982 Nov;70(5):1081–1091. doi: 10.1172/JCI110696. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES